News & Updates

Kirsten rat sarcoma viral oncogene (KRAS) mutations are common in non-small cell lung cancer (NSCLC) and are associated with poor prognosis, likely due to poor responses to most systemic therapies and lack of targeted therapies. At a recent webinar organized by Amgen, Associate Professor Daniel Tan from the National Cancer Centre, Singapore, gave an overview of the biomarker testing landscape in NSCLC. Associate Professor Thomas John from the Peter MacCallum Hospital, Australia, addressed the optimal treatment strategy for KRAS-mutant NSCLC and the role of sotorasib, a first-in-class RAS GTPase family inhibitor approved in Singapore for the treatment of adults with KRAS^G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy.

External beam radiation therapy with low-dose rate brachytherapy boost appears to result in worse urinary irritative/obstructive and bowel functions but better urinary incontinence function through 5 years after treatment when compared to radical prostatectomy, reports a recent study.